Physician profile
Daniel P Arrison
NPI 1699727370
$8,590.24
in general payments reported to CMS, 2019-2025
58 companies · $1,660 in 2025
The $1,660 reported for 2025 was more than what 75% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $359 · 2021: $488 · 2022: $1,402 · 2023: $2,393 · 2024: $1,470 · 2025: $1,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,412 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,411.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $853.40 | 2019-2025 | Myrbetriq, Xtandi |
| Abbvie INC. | $809.45 | 2019-2025 | Botox |
| Sumitomo Pharma America, INC. | $776.32 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $718.21 | 2019-2025 | Erleada, Akeega, Carvykti |
| Bayer Healthcare Pharmaceuticals INC. | $452.72 | 2019-2025 | |
| Antares Pharma, INC. | $328.41 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Endo Pharmaceuticals INC. | $327.71 | 2019-2024 | Xiaflex, Aveed |
| Dornier Medtech America, INC | $305.65 | 2023 | Dornier Medtech |
| Novartis Pharmaceuticals Corporation | $239.72 | 2019-2025 | |
| Tolmar, INC. | $239.09 | 2023-2025 | Eligard, Jatenzo |
| Pfizer INC. | $231.98 | 2019-2025 | |
| Coloplast Corp | $227.44 | 2019-2024 | Speedicath |
| Medtronic, INC. | $194.26 | 2022-2023 | Interstim |
| Progenics Pharmaceuticals, INC. | $191.84 | 2022-2025 | Pylarify |
| Olympus America INC. | $189.27 | 2023-2025 | Itind System, Soltive |
Show all 56 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Arrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.